AdAlta Ltd (ASX:1AD) CEO and managing director Tim Oldham speaks with Proactive about the significant progress being made with expanding the potential disease areas (indications) and routes of delivery for AD-214. The company is transitioning its focus from inhalant to injectable delivery. Oldham also discusses future priorities for AD-214.
AdAlta makes significant progress in expanding value of AD-214
